OTCMKTS:CVSI

CV Sciences Stock Forecast, Price & News

$0.38

-0.01 (-2.84 %)

(As of 06/18/2021 03:59 PM ET)

Add

Compare

Today's Range

$0.38

▼

$0.41

50-Day Range

$0.36

▼

$0.50

52-Week Range

$0.35

▼

$1.12

Volume310,500 shs

Average Volume937,132 shs

Market Capitalization$41.34 million

P/E RatioN/A

Dividend YieldN/A

Beta0.29

30 days | 90 days | 365 days | Advanced Chart

Receive CVSI News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

About CV Sciences

CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Cantor Updates Ratings On Several Cannabis And CBD Stocks - MedMen, Jushi, cbdMD, CV Sciences
June 18, 2021 | markets.businessinsider.com

Short Interest in CV Sciences, Inc. (OTCMKTS:CVSI) Rises By 24.8%
June 17, 2021 | americanbankingnews.com

CV Sciences, Inc.(CVSI)
June 11, 2021 | fool.com

CV Sciences, Inc. (OTCMKTS:CVSI) Receives Consensus Rating of "Hold" from Brokerages
June 2, 2021 | americanbankingnews.com

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q1 2021 Results - Earnings Call Transcript
May 15, 2021 | seekingalpha.com

CV Sciences, Inc. Reports First Quarter 2021 Financial Results
May 13, 2021 | finance.yahoo.com

CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep Gummies
May 11, 2021 | finance.yahoo.com

Will CV Sciences, Inc. (CVSI) Report Negative Q1 Earnings? What You Should Know
May 7, 2021 | finance.yahoo.com

CV Sciences, Inc. to Announce First Quarter 2021 Results on May 13, 2021
May 6, 2021 | finance.yahoo.com

CV Sciences and Alkemist Labs Form Partnership to Support the National Institute of Standards and Technology’s Cannabis Quality Assurance Program
April 13, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CVSI
Previous SymbolNASDAQ:CVSI
CUSIPN/A
CIK1510964
Webwww.cvsciences.com
Phone866-290-2157
Employees91
Year FoundedN/A

Sales & Book Value

Annual Sales$24.43 million
Price / Sales1.69
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.11 per share
Price / Book3.45

Profitability

EPS (Most Recent Fiscal Year)($0.22)
Net Income$-22,280,000.00
Net Margins-96.46%
Return on Equity-125.42%
Return on Assets-55.73%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares108,805,000
Market Cap$41.34 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.25 out of 5 stars

Medical Sector

916th out of 2,101 stocks

Pharmaceutical Preparations Industry

444th out of 831 stocks

3.1 Analyst's Opinion

Consensus Rating
CV Sciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $0.68, CV Sciences has a forecasted upside of 77.7% from its current price of $0.38.
Amount of Analyst Coverage
CV Sciences has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
CV Sciences has received 214 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CV Sciences has received 207 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CV Sciences has received 50.83% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CV Sciences and other stocks. Vote “Outperform” if you believe CVSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVSI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
CV Sciences does not currently pay a dividend.
Dividend Growth
CV Sciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CV Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.80% of the stock of CV Sciences is held by insiders.
Percentage Held by Institutions
Only 0.02% of the stock of CV Sciences is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for CV Sciences are expected to grow in the coming year, from ($0.10) to ($0.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CV Sciences is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CV Sciences is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CV Sciences has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions

Is CV Sciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CV Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVSI, but not buy additional shares or sell existing shares.
View analyst ratings for CV Sciences or view top-rated stocks.

What stocks does MarketBeat like better than CV Sciences?

Wall Street analysts have given CV Sciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CV Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CV Sciences?

CV Sciences saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,055,300 shares, an increase of 24.8% from the May 13th total of 845,700 shares. Based on an average daily volume of 785,300 shares, the short-interest ratio is currently 1.3 days.
View CV Sciences' Short Interest.

When is CV Sciences' next earnings date?

CV Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for CV Sciences.

How were CV Sciences' earnings last quarter?

CV Sciences, Inc. (OTCMKTS:CVSI) announced its quarterly earnings data on Wednesday, March, 17th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.07. The business earned $5.20 million during the quarter, compared to the consensus estimate of $6.71 million. CV Sciences had a negative trailing twelve-month return on equity of 125.42% and a negative net margin of 96.46%.
View CV Sciences' earnings history.

How has CV Sciences' stock been impacted by Coronavirus?

CV Sciences' stock was trading at $0.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CVSI stock has decreased by 36.7% and is now trading at $0.3799.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CVSI?

4 Wall Street analysts have issued twelve-month target prices for CV Sciences' shares. Their forecasts range from $0.50 to $0.95. On average, they anticipate CV Sciences' share price to reach $0.68 in the next year. This suggests a possible upside of 77.7% from the stock's current price.
View analysts' price targets for CV Sciences or view top-rated stocks among Wall Street analysts.

Who are CV Sciences' key executives?

CV Sciences' management team includes the following people:

Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 64, Pay $378.6k)
Mr. Joerg Grasser, Chief Financial Officer (Age 46, Pay $214.71k)
Dr. Douglas Jesse MacKay ND, Sr. VP of Scientific & Regulatory Affairs (Age 48, Pay $195.19k)
Mr. Tim Hitchman, VP of Operations
Mr. Stuart Tomc, Sr. VP of Human Nutrition
Mr. Jesse Karagianes, Sr. VP of Revenue Growth

Who are some of CV Sciences' key competitors?

Some companies that are related to CV Sciences include Assembly Biosciences (ASMB), Oasmia Pharmaceutical AB (publ) (OASMY), Actinium Pharmaceuticals (ATNM), IMV (IMV), Hepion Pharmaceuticals (HEPA), Qilian International Holding Group (QLI), Genprex (GNPX), Oncolytics Biotech (ONCY), Antibe Therapeutics (ATBPF), Flora Growth (FLGC), Tiziana Life Sciences (TLSA), ContraFect (CFRX), SCYNEXIS (SCYX), Calithera Biosciences (CALA) and Adamis Pharmaceuticals (ADMP).
View all of CVSI's competitors.

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), (APHA), OrganiGram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA).

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How do I buy shares of CV Sciences?

Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $0.38.

How much money does CV Sciences make?

CV Sciences has a market capitalization of $41.34 million and generates $24.43 million in revenue each year. The company earns $-22,280,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does CV Sciences have?

CV Sciences employs 91 workers across the globe.

What is CV Sciences' official website?

The official website for CV Sciences is www.cvsciences.com.

Where are CV Sciences' headquarters?

CV Sciences is headquartered at 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121.

How can I contact CV Sciences?

CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected]

This page was last updated on 6/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here